Epidemiology and Comorbidities of Polycystic Ovary Syndrome in an Indigent Population

被引:58
|
作者
Sirmans, Susan M. [1 ]
Parish, Roy C. [1 ,2 ]
Blake, Sandra [3 ]
Wang, Xiaojun [3 ]
机构
[1] Univ Louisiana Monroe, Sch Pharm, Baton Rouge, LA 70806 USA
[2] Louisiana State Univ, Sch Med, Dept Internal Med, Hlth Sci Ctr, Shreveport, LA USA
[3] Univ Louisiana Monroe, Coll Pharm, Off Outcomes Res, Baton Rouge, LA 70806 USA
关键词
polycystic ovary syndrome; cardiovascular risk factors; anxiety; bipolar disorders; depression; eating disorders; infertility; obstructive sleep apnea; IMPAIRED GLUCOSE-TOLERANCE; OBSTRUCTIVE SLEEP-APNEA; INCREASED PREVALENCE; BIPOLAR DISORDER; COMMUNITY SAMPLE; INCREASED RISK; OBESE WOMEN; CORONARY; HEALTH; ATHEROSCLEROSIS;
D O I
10.1097/01.JIM.0000446834.90599.5d
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age. The aims of this study were to provide an estimate of the prevalence of PCOS in clinical practice; compare the risk of established cardiovascular risk factors, cardiovascular disease, and other comorbid conditions in women with PCOS to that of age-and race-matched controls; and explore the total costs of care that can be attributed to PCOS. Methods: Louisiana Medicaid claims data were used to identify women with PCOS or its defining features and a control group in a ratio of 1: 3. The prevalence of PCOS, cardiovascular risk factors (diabetes, dyslipidemia, dysmetabolic syndrome, glucose intolerance, hypertension, and obesity), key comorbidities (anxiety, bipolar disorders, depression, eating disorders, infertility, obstructive sleep apnea), and diagnosed cardiovascular disease were measured. Results: During 2010, the prevalence of PCOS was 0.88%. Women with PCOS were more likely to have a diagnosis of diabetes (odds ratio [OR], 4.35; 95% confidence interval [CI], 3.63-5.21), dyslipidemia (OR, 3.56; 95% CI, 3.04-4.19), dysmetabolic syndrome (OR, 23.46; 95% CI, 13.64-40.36), glucose intolerance (OR, 5.46; 95% CI, 3.10-9.60), hypertension (OR, 2.76; 95% CI, 2.41-3.18), obesity (OR, 5.79; 95% CI, 5.07-6.62), infertility (OR, 23.42; 95% CI, 10.63-51.61), obstructive sleep apnea (OR, 6.47; 95% CI, 3.62-11.55), anxiety (OR, 1.76; 95% CI, 1.53-2.04), bipolar disorders (OR, 1.94; 95% CI, 1.55-2.44), and depression (OR, 2.22; 95% CI, 1.94-2.54) than did controls. Average total costs of care for the year was $5551 in the PCOS group and $3496 in the control group. After controlling for the effects of other variables, the average total cost of care for PCOS was $637 higher than that of the control group. Other variables that contributed significantly to the total costs of care included race, age, acute myocardial infarction, transient ischemic attack, peripheral artery disease, anxiety, depression, bipolar disorders, hypertension, diabetes, and dyslipidemia. Conclusions: Although the clinical burden of PCOS is high, it is diagnosed less frequently in clinical practice compared with systematic screening studies. This is concerning considering that PCOS is associated with cardiovascular risk factors and other comorbidities. Mean total costs of care for the PCOS group was higher than the mean total costs of care for the control group. Polycystic ovary syndrome is independently associated with an increase in mean total costs of care.
引用
收藏
页码:868 / 874
页数:7
相关论文
共 50 条
  • [11] Comorbidities and complications of polycystic ovary syndrome: An overview of systematic reviews
    Gilbert, Emily W.
    Tay, Chau T.
    Hiam, Danielle S.
    Teede, Helena J.
    Moran, Lisa J.
    CLINICAL ENDOCRINOLOGY, 2018, 89 (06) : 683 - 699
  • [12] Physician Knowledge of Polycystic Ovary Syndrome Diagnosis and Comorbidities.
    Stevenson, Micaela
    Adkins, Tyler
    Smith, Yolanda
    Moravek, Molly
    REPRODUCTIVE SCIENCES, 2020, 27 (SUPPL 1) : 360A - 361A
  • [13] Polycystic ovary syndrome: a reproductive and metabolic web of risk, comorbidities, and disease
    Bates, G. Wright, Jr.
    FERTILITY AND STERILITY, 2019, 111 (03) : 471 - 472
  • [14] Graves' disease could increase polycystic ovary syndrome and comorbidities in Taiwan
    Chen, Hsin-Hung
    Chen, Ching-Chu
    Hsieh, Ming-Chia
    Ho, Chun-Wei
    Hsu, Sheng-Pang
    Yip, Hei-Tung
    Kao, Chia-Hung
    CURRENT MEDICAL RESEARCH AND OPINION, 2020, 36 (06) : 1063 - 1067
  • [15] Diagnosis, Management, and Associated Comorbidities of Polycystic Ovary Syndrome: A Narrative Review
    Choudhari, Rutuja
    Tayade, Surekha
    Tiwari, Aakriti
    Satone, Prasiddhi
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (04)
  • [16] Prevalence, Phenotypes, and Comorbidities of Polycystic Ovary Syndrome Among Indian Women
    Ganie, Mohd Ashraf
    Chowdhury, Subhankar
    Malhotra, Neena
    Sahay, Rakesh
    Bhattacharya, Prasanta Kumar
    Agrawal, Sarita
    Jabbar, P. K.
    Suri, Vanita
    Rozati, Roya
    Sreenivas, Vishnubhatla
    Baba, Mohammad Salem
    Wani, Imtiyaz Ahmad
    Rashid, Haroon
    Nair, Abhilash
    Shukla, Amlin
    Arora, Taruna
    Kulkarni, Bharati
    JAMA NETWORK OPEN, 2024, 7 (10)
  • [17] Natural History of Polycystic Ovary Syndrome and New Advances in the Epidemiology
    Piltonen, Terhi T.
    Arffman, Riikka K.
    Joham, Anju E.
    SEMINARS IN REPRODUCTIVE MEDICINE, 2021, 39 (03/04) : 94 - 101
  • [18] Epidemiology, pathogenesis, genetics & management of polycystic ovary syndrome in India
    Ganie, Mohammad Ashraf
    Vasudevan, Vishnu
    Wani, Imtiyaz Ahmad
    Baba, Mohammad Salem
    Arif, Tasleem
    Rashid, Aafia
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2019, 150 (04) : 333 - 344
  • [19] The epidemiology of polycystic ovary syndrome - Prevalence and associated disease risk
    Solomon, CG
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 1999, 28 (02) : 247 - +
  • [20] Population and Diagnostic Characteristics of Polycystic Ovary Syndrome and Hyperandrogenism
    Douglas, Crystal Clark
    Rojo, Juan Ulises
    WOMENS HEALTH REPORTS, 2024, 5 (01): : 945 - 953